Cantargia AB (ST:CANTA) — Market Cap & Net Worth
Market Cap & Net Worth: Cantargia AB (CANTA)
Cantargia AB (ST:CANTA) has a market capitalization of $48.75 Million (Skr452.97 Million) as of August 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21909 globally and #410 in its home market, demonstrating a -4.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cantargia AB's stock price Skr1.82 by its total outstanding shares 248611655 (248.61 Million). See capital reinvestment ratio of Cantargia AB to understand how much of operating cash flow is reinvested back into capital assets.
Cantargia AB Market Cap History: 2015 to 2026
Cantargia AB's market capitalization history from 2015 to 2026. Data shows change from $199.58 Million to $48.75 Million (-10.68% CAGR).
Cantargia AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cantargia AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CANTA by Market Capitalization
Companies near Cantargia AB in the global market cap rankings as of August 3, 2026.
Key companies related to Cantargia AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Cantargia AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Cantargia AB's market cap moved from $199.58 Million to $ 48.75 Million, with a yearly change of -10.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr48.75 Million | -56.46% |
| 2025 | Skr111.97 Million | +147.63% |
| 2024 | Skr45.22 Million | -54.79% |
| 2023 | Skr100.01 Million | +21.36% |
| 2022 | Skr82.40 Million | -79.95% |
| 2021 | Skr411.01 Million | -71.16% |
| 2020 | Skr1.42 Billion | +217.62% |
| 2019 | Skr448.64 Million | +41.90% |
| 2018 | Skr316.16 Million | +121.87% |
| 2017 | Skr142.50 Million | +1.24% |
| 2016 | Skr140.76 Million | -29.47% |
| 2015 | Skr199.58 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Cantargia AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.75 Million USD |
| MoneyControl | $48.75 Million USD |
| MarketWatch | $48.75 Million USD |
| marketcap.company | $48.75 Million USD |
| Reuters | $48.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more